Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2008

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2010

Conditions
Heparin-Induced Thrombocytopenia
Interventions
DRUG

fondaparinux

fondaparinux subcutaneous injection once daily until INR stable in therapeutic range, at least five days: 5 mg if less than 50 kg, 7.5 mg if 50-100 kg, 10 mg if \>100 kg

DRUG

argatroban or lepirudin

continuous infusion titrated into therapeutic range and for at least 5 days and until INR stable in therapeutic range

Sponsors
All Listed Sponsors
collaborator

University of Tennessee

OTHER

lead

Methodist Healthcare

OTHER

NCT00603824 - Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT) | Biotech Hunter | Biotech Hunter